retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity Efficacy and safety of retatrutide, a GIP, GLP-1, and receptor agonist, in people with type diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 Is retatrutide better than tirzepatide?

Ice crystal formation can damage the peptide structure and reduce potency

doi:10.1152/ajpendo.1985.249.6.E603 328

The discovery journey also revealed that GLP-1 therapy works best as part of a comprehensive metabolic strategy, combined with lifestyle modifications and sometimes genetic testing

Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes

Because new Phase 3 obesity results announced in May 2026 drew major attention to its weight-loss potential

Programs that can offer both, along with oral and injectable formats, give patients more room to find what actually works for their body